SOAT1 and Thrombocytopenia: The potential risk of thrombocytopenia via suppressing JAK/STAT pathway may also raise the pre-cautions about several ongoing anti-tumor therapies aiming at suppressing this pathway, such as the chimeric antigen receptor therapy containing JAK/STAT domain [29], in which the occurrence thrombocytopenia may become a crucial factor to balance between benefit and risk of treatment.